2023
Use of Wearable Devices in Individuals With or at Risk for Cardiovascular Disease in the US, 2019 to 2020
Dhingra L, Aminorroaya A, Oikonomou E, Nargesi A, Wilson F, Krumholz H, Khera R. Use of Wearable Devices in Individuals With or at Risk for Cardiovascular Disease in the US, 2019 to 2020. JAMA Network Open 2023, 6: e2316634. PMID: 37285157, PMCID: PMC10248745, DOI: 10.1001/jamanetworkopen.2023.16634.Peer-Reviewed Original ResearchConceptsHealth Information National Trends SurveyUS adultsExacerbate disparitiesWearable device usersCardiovascular diseaseCardiovascular healthPopulation-based cross-sectional studySelf-reported cardiovascular diseaseCardiovascular disease risk factorsNational Trends SurveyOverall US adult populationCardiovascular risk factor profileSelf-reported accessAssociated with lower useUse of wearable devicesImprove cardiovascular healthLower household incomeLower educational attainmentUS adult populationRisk factor profileNationally representative sampleCross-sectional studyProportion of adultsTrends SurveyWearable device data
2020
Association of Body Mass Index and Age With Morbidity and Mortality in Patients Hospitalized With COVID-19
Hendren NS, de Lemos JA, Ayers C, Das SR, Rao A, Carter S, Rosenblatt A, Walchok J, Omar W, Khera R, Hegde AA, Drazner MH, Neeland IJ, Grodin JL. Association of Body Mass Index and Age With Morbidity and Mortality in Patients Hospitalized With COVID-19. Circulation 2020, 143: 135-144. PMID: 33200947, DOI: 10.1161/circulationaha.120.051936.Peer-Reviewed Original ResearchConceptsBody mass indexClass III obesityHospital deathMechanical ventilationHigh riskVenous thromboembolismObese patientsMass indexObese individualsAmerican Heart Association COVID-19 Cardiovascular Disease RegistryAssociation of BMIMajor adverse cardiac eventsHigher body mass indexCOVID-19Significant body mass indexClass ICardiovascular Disease RegistryGeneralizable patient populationsAdverse cardiac eventsPrimary end pointCOVID-19 prevention strategiesCOVID-19 outcomesCoronavirus disease 2019Public health messagingAdults 51
2018
Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis
Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, Neeland IJ, Berry JD, Camilleri M, Singh S. Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis. Gastroenterology 2018, 154: 1309-1319.e7. PMID: 29305933, PMCID: PMC5880739, DOI: 10.1053/j.gastro.2017.12.024.Peer-Reviewed Original ResearchConceptsWeight loss medicationsCardiometabolic risk profileHigh-density lipoprotein cholesterolWaist circumferenceDrug AdministrationSystematic reviewRisk profileLipoprotein cholesterolHemoglobin A1cObese adultsCholesterol profileSystolic/diastolic BPCardiometabolic risk factorsNetwork Meta-AnalysisRandomized clinical trialsQuality of evidenceLow-density lipoproteinModest decreaseOutcomes of interestEffect of foodLong-term useMinimal effectLiraglutide useOrlistat useBlood pressure
2017
Persistent socioeconomic disparities in cardiovascular risk factors and health in the United States: Medical Expenditure Panel Survey 2002–2013
Valero-Elizondo J, Hong JC, Spatz ES, Salami JA, Desai NR, Rana JS, Khera R, Virani SS, Blankstein R, Blaha MJ, Nasir K. Persistent socioeconomic disparities in cardiovascular risk factors and health in the United States: Medical Expenditure Panel Survey 2002–2013. Atherosclerosis 2017, 269: 301-305. PMID: 29254694, DOI: 10.1016/j.atherosclerosis.2017.12.014.Peer-Reviewed Original ResearchConceptsCardiovascular diseaseSocioeconomic statusWorse cardiovascular risk factor profileCardiovascular risk factor profileHighest prevalence increasePrevalence of CRFCardiovascular risk factorsRisk factor profileHealthy lifestyle behaviorsMedical Expenditure Panel Survey 2002Medical Expenditure Panel SurveyHealth disparity gapRelative percent increasePhysical inactivityLifestyle behaviorsRisk factorsPrevalence increasesHigh burdenHigh prevalenceLow-income groupsProportion of individualsUS adultsFactor profileDisparity gapSocioeconomic disparities
2016
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA 2016, 315: 2424-2434. PMID: 27299618, PMCID: PMC5617638, DOI: 10.1001/jama.2016.7602.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdverse eventsClinical trialsWeight lossObese adultsHigher oddsAdverse event-related treatment discontinuationSystematic reviewSignificant excess weight lossCumulative ranking (SUCRA) probabilitiesDiscontinuation of therapyExcess weight lossProportion of patientsManagement of obesityQuality of evidenceWeight loss agentsWeb of ScienceTreatment discontinuationCochrane CENTRALPharmacological treatmentMagnitude of decreaseGRADE criteriaDrug treatmentLiraglutideMAIN OUTCOMEPlacebo participants